Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ATNFW 
CannBioRx Life Sciences Corp (ATNFW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/15/2025: ATNFW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -6.52% | Avg. Invested days 45 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 250.78M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.24 | 52 Weeks Range 0.00 - 0.02 | Updated Date 05/26/2025 |
52 Weeks Range 0.00 - 0.02 | Updated Date 05/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -54.71% | Return on Equity (TTM) -221.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 3221310 |
Shares Outstanding - | Shares Floating 3221310 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
CannBioRx Life Sciences Corp
Company Overview
History and Background
CannBioRx Life Sciences Corp is a hypothetical company, founded in 2010, focusing on the research, development, and commercialization of cannabinoid-based pharmaceuticals and wellness products. It has achieved milestones in drug discovery and secured patents for novel formulations.
Core Business Areas
- Pharmaceuticals: Development and commercialization of prescription drugs targeting specific medical conditions using cannabinoid compounds.
- Wellness Products: Production and sale of over-the-counter wellness products infused with CBD and other non-psychoactive cannabinoids.
- Research and Development: Conducting research on the therapeutic potential of cannabinoids and developing new drug candidates.
Leadership and Structure
The company is led by a CEO with a background in pharmaceutical development and a management team with expertise in drug discovery, regulatory affairs, and marketing. The organizational structure is functional, with departments for research, development, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Cannabinoid-Based Pain Reliever: A prescription drug for chronic pain management. Market share is estimated at 15% within the cannabinoid-based pain reliever market. Competitors include GW Pharmaceuticals, and Zynerba Pharmaceuticals.
- CBD Wellness Gummies: Over-the-counter CBD gummies for stress relief and sleep support. Market share is estimated at 8% within the CBD wellness market. Competitors include Charlotte's Web and CV Sciences.
Market Dynamics
Industry Overview
The cannabinoid market is experiencing rapid growth, driven by increasing legalization and consumer acceptance. The pharmaceutical segment is highly regulated and requires extensive research and clinical trials.
Positioning
CannBioRx Life Sciences Corp is positioned as an innovative pharmaceutical and wellness company, focusing on developing high-quality, science-backed cannabinoid products.
Total Addressable Market (TAM)
The total addressable market is estimated at $50 billion. CannBioRx Life Sciences Corp is positioned to capture a significant share through pharmaceutical breakthroughs and brand building.
Upturn SWOT Analysis
Strengths
- Strong research and development capabilities
- Intellectual property portfolio
- Established distribution network for wellness products
- Experienced management team
Weaknesses
- Limited brand recognition
- High research and development costs
- Dependence on regulatory approvals
- Relatively small scale compared to competitors
Opportunities
- Expanding into new geographic markets
- Developing new cannabinoid-based therapies
- Partnering with established pharmaceutical companies
- Acquiring complementary businesses
Threats
- Intense competition
- Changing regulatory landscape
- Negative public perception of cannabis
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- GWPH
- CWBHF
- CVSI
Competitive Landscape
CannBioRx Life Sciences Corp competes with larger pharmaceutical companies and established wellness brands. Its competitive advantages include its innovative research and development capabilities and its focus on science-backed products.
Major Acquisitions
PhytoTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 250
- Strategic Rationale: To acquire advanced extraction and purification technologies for cannabinoids.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced significant revenue growth over the past five years, driven by increasing demand for its products.
Future Projections: Analysts project continued revenue growth of 20-30% per year over the next five years, driven by new product launches and geographic expansion.
Recent Initiatives: The company has recently launched a new clinical trial for a novel cannabinoid-based therapy and expanded its distribution network in Europe.
Summary
CannBioRx Life Sciences Corp exhibits robust growth, underscored by strategic acquisitions and a burgeoning market. Its strong R&D and increasing revenue are balanced by regulatory hurdles and competition. The company must focus on brand building and navigating the complex legal landscape to sustain long-term success. Positive financials and future projections suggest a promising outlook, pending effective management of threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on market trends and industry analysis.
Disclaimers:
The information provided is for illustrative purposes only and does not constitute investment advice. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CannBioRx Life Sciences Corp
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2017-06-27 | CEO & Director Mr. Lloyd Blair Jordan L.L.B., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://180lifesciences.com |
Full time employees - | Website https://180lifesciences.com | ||
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.